Lipoic Acid—A Novel Therapeutic Approach for Multiple Sclerosis

a report by

Vijayshree Yadav, MD, MCR, Gail Marracci, PhD and Dennis N Bourdette, MD

Oregon Health and Science University

DOI: 10.17925/USN.2008.04.02.12

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that has its symptom onset primarily in young and middle-aged adults. Approximately 400,000 Americans are affected by this chronic and disabling disease, with a significant burden placed on the affected person and his or her family, the healthcare system, and society. MS was described as a clinicopathological entity in the mid-19th century, but significant progress in understanding its pathogenesis has been made only in the past few decades. It is now well established that a dysregulated immune system that targets CNS myelinated tissue including brain, spinal cord, and optic nerves causes MS. Inflammation, focal demyelination, and axonal and neuronal loss are prominent features of the pathology. What triggers the autoimmune response is still not understood. However, our understanding of the pathogenesis of MS has led to the development of treatments that alter the course of the disease.

Until 1993 there were no US Food and Drug Administration (FDA)-approved drugs for MS. Recombinant interferon beta 1b (Betaseron®) became the first disease-modifying treatment available for the illness. Since then, five other FDA-approved drugs have become available for MS treatment. These include two forms of recombinant interferon beta 1a (Avonex®, Rebif®), glatiramer acetate (Copaxone®), mitoxantrone (Novantrone®), and natalizumab (Tysabri®). The interferons and glatiramer acetate work by modulating the immune system and lead to upregulation of the anti-inflammatory response and downregulation of the pro-inflammatory response in MS. Natalizumab is a monoclonal antibody to alpha 1 integrin molecule (VLA-4), reduces the ability of activated T cells to cross the blood–brain barrier (BBB).

All of these medications reduce disease activity in MS, although none is curative. Despite the availability of these six drugs, there remains a significant need for additional drugs for MS. The use of currently available drugs is limited in that all are available only as injections, are expensive, and can cause significant side effects. Therefore, there is considerable interest in the development of safe oral treatments for MS.

Lipoic acid (LA) is a naturally occurring antioxidant that is available as an over-the-counter dietary supplement in the US. LA as a therapy for diabetic neuropathy has been evaluated in several clinical trials.1-4 LA is available in oral as well as intravenous formulations in Germany for the treatment of diabetic neuropathy. LA has also been tested as an effective therapy for an animal model of MS, and a phase I trial of LA has been completed in MS.5 LA protects the cell from free radicals that result from intermediate metabolites or from the degradation of exogenous molecules and from heavy metals, thus functioning as a potent antioxidant. LA also has a significant role in cellular carbohydrate metabolism. In its R-form, LA serves as a co-factor for five mitochondrial proteins that have a central role in oxidative metabolism when covalently bound to a lysine residue (lipoamide; lipoyllysine); these five proteins are the acyltransferase component of the pyruvate complex, α-ketoglutarate, the branched-chain α-ketoacid dehydrogenase complexes, pyruvate...
The transmigration of activated immune cells across the blood–brain barrier plays a significant role in multiple sclerosis (MS) pathogenesis as it leads to the development of new inflammatory lesions in MS.

Clinical trials have suggested that serum mean MMP-9 levels are increased in MS patients with clinical and magnetic resonance imaging (MRI) disease activity and that a shift in MMP-9/TIMP-1 balance toward proteolytic activity of MMP-9 could be relevant in MS immune dysregulation, whereas the MMP-9/TIMP-1 ratio in serum showed higher (p=0.04) values in stable relapsing–remitting MS (RRMS) than primary progressive (PP) but also in active patients, evaluated either clinically (p=0.006) or from the MRI (p<0.05), compared with inactive disease. In addition, increased serum levels of sICAM-1 have been associated with inflammatory disease activity and with the appearance of gadolinium enhancing lesions on brain MRI. Studies have shown that upregulated adhesion molecules in blood and serum could indicate ongoing inflammation in the CNS in MS subjects.

The role of cytokines in MS pathogenesis is evident by correlations that exist between expression of pro-inflammatory cytokines during periods of clinical worsening and of regulatory cytokines during periods of clinical remission. Increased levels of pro-inflammatory cytokines such as TNF-α, IFN-γ, and interleukin 2 (IL-2) have been found in the peripheral blood, CSF, and brain lesions of MS patients. Anti-inflammatory cytokines that include IL-4 and IL-10 are expressed during remission. Numerous reports document the association between these pro-inflammatory cytokines and disease activity, thus implicating them as mediators of immunopathogenesis in MS.

Macrophages and Oxidative Injury in Multiple Sclerosis

In addition to the role of T and B cells in MS pathogenesis, activated macrophages and microglia also play a significant role in tissue destruction as well as repair. Macrophages produce pro-inflammatory enzymes such as proteases, lipases, and cytokines and special molecules such as osteopontin that destroy tissues in a variety of ways. In addition, macrophages are a source of reactive oxygen and nitrogen species, thus causing oxidative damage.

Therapeutic agents that target adhesion molecules and MMP-9 may prove useful as treatments for MS and other neurological diseases in which migration of inflammatory cells plays a pathogenic role. A growing body of literature exists that demonstrates the ability of LA to reduce the expression of surface adhesion molecules on endothelial cells, suppress MMP-9 activity, and inhibit the trafficking of inflammatory cells across the BBB. Taken together, these data provide evidence for the further evaluation of LA as a therapeutic agent in MS.

Animal Model of Multiple Sclerosis—Experimental Autoimmune Encephalomyelitis

As a widely used model of MS, experimental autoimmune encephalomyelitis (EAE) has provided important insights into the immunopathogenesis of MS and led to the development of new therapeutic
Multiple Sclerosis

approaches for treating MS. EAE can be induced in a variety of animal species, including mice, rats, and rhesus macaques. EAE in Swiss/Jackson Laboratory (SJL) mice is characterized by an acute episode of paralysis followed by recovery and then spontaneous relapses of paralysis. This chronic relapsing model of EAE is similar to relapsing–remitting MS, which is the clinical pattern that is most frequently seen in patients at the time of their initial diagnosis. Secondary progressive MS is represented best by the C57BL6 EAE model; this form of MS is seen in many patients following relapsing–remitting disease. EAE in C57BL6 is characterized by acute paralysis from which mice do not recover followed by a slow clinical worsening without relapse. Similar to MS patients, histopathological examination of spinal cords from mice with EAE reveals multifocal areas of demyelination with axonal loss in the spinal cord associated with inflammatory infiltrates composed of lymphocytes and macrophages.

Lipoic Acid and Experimental Autoimmune Encephalomyelitis
LA suppresses and treats EAE in the SJL mouse model. When administered prior to disease onset, LA successfully suppressed the clinical course of EAE in a dose-dependent fashion (25–50–100mg/kg/day), with complete suppression achieved at 100mg/kg/day over a 45-day treatment period. Importantly, when LA was administered after the onset of the disease, the clinical severity of EAE greatly diminished. Histopathological examination of spinal cords from mice that received LA revealed a significant reduction in inflammatory infiltrates and axonal damage. The ability of LA to suppress and treat EAE in a second mouse model (C57BL6 mice immunized with MOG 35-55 peptide) and in a rat model of EAE has been confirmed by others.

LA inhibits MMP-9 activity directly and at the level of transcription. Moreover, LA was shown to inhibit migration of the human Jurkat T cell line across an extracellular matrix barrier in vitro. In vitro, immunohistochemical staining of spinal cords from mice treated with LA revealed a reduction in the expression of adhesion molecules VCAM-1 and ICAM-1 from the surface of endothelial cells. Similar studies have demonstrated that LA reduces EAE in rats in part by reducing the permeability of the BBB and decreasing the migratory capacity of monocytes to enter the CNS.

Therapeutic agents that target adhesion molecules and MMP-9 may prove useful as treatments for multiple sclerosis and other neurological diseases in which migration of inflammatory cells plays a pathogenic role.

In addition, LA has also been reported to induce the generation of cyclic adenosine monophosphate (cAMP) in human T-cells and natural killer (NK) cells in a concentration-dependent fashion. Pharmacological inhibitors of the EP2 and EP4 prostaglandin receptors blocked the ability of LA to stimulate the generation of cAMP, suggesting that LA may be acting as an agonist of these G-protein coupled receptors. In the presence of LA, IL-12/LIF-18-induced secretion of IFN-γ by NK cells was significantly decreased. In addition, using a lactate dehydrogenase release assay, it was demonstrated that pre-treatment with LA significantly diminished the ability of NK cells to lyse target K562 cells. It is thought that a subset of NK cells may contribute to the disease severity observed in MS. These findings suggest that LA may modulate the activation and function of NK cells and that in the presence of LA NK cells may become less pathogenic. Taken together, these data suggest that in addition to its direct effects on oxidative stress as an antioxidant, LA may have non-antioxidant properties that are therapeutic in EAE and MS.

Clinical Trials
A single clinical trial of LA in MS patients has taken place. This was a placebo-controlled, double-blind, randomized phase I trial that looked at the safety and tolerability of different doses of oral LA. In addition, this study explored the pharmacokinetics (PK) of LA and the effects of LA on serum immune markers, including MMP-9 and sICAM-1, after two weeks of LA administration. The study included 37 MS subjects who were randomly assigned to one of four groups: placebo, LA 600mg twice a day, LA 1,200mg once a day, or LA 1,200mg twice a day. Subjects received the study drug for 14 days. The PK sera were collected at eight time-points. The first blood draw was just before taking the first dose of the study drug, followed by collections at 15, 30, 60, 120, 180, and 240 minutes and 24 hours after ingestion of the first dose of study drug. Maximum serum concentration of LA (Cmax) correlated with dose and varied considerably among subjects. Subjects who took 1,200mg LA had substantially higher Cmax levels (range 0–19µg/ml) than those taking 600mg LA (range 0–3.7µg/ml).

Authors also explored the effects of LA Cmax on the levels of serum MMP-9. The baseline MMP-9 levels were obtained prior to patients receiving the study drug. Subsequent MMP-9 levels were measured at three additional time-points. These included 24 hours after the study initiation (visit three of study), at one week (visit four of study), and at the end of two weeks (visit five) of the study. The outcome measure was the mean change in MMP-9 levels compared with baseline and visits three, four, and five. A significant negative correlation between the LA Cmax values and the MMP-9 mean change (Kendall’s tau=0.263; p<0.04) was observed.

The outcome measure was to evaluate the relationship between LA and serum sICAM-1 levels with the mean change between visits three, four, and five compared with baseline sICAM-1. Those subjects who took higher doses of LA showed the greatest decrease in sICAM-1 (Jonckheere-Terpstra test; p=0.03), suggesting a significant dose–response relationship between LA dose and the mean change in sICAM-1.

Safety data revealed that high-dose LA was generally safe and well tolerated. Nausea, mild gastrointestinal discomfort, and strange odor in the urine were minor complaints of some subjects in the study. One subject developed a reversible disseminated maculopapular allergic rash with fever that required discontinuation of LA.

Further studies to better understand the mechanism of action of lipoic acid are under way.
Lipoic Acid—A Novel Therapeutic Approach for Multiple Sclerosis

Since LA made by various manufacturers is available over the counter and drug manufacturing is not regulated by the FDA, it is critical that we have rigorous PK studies that validate various LA formulations. Yadav and colleagues have recently completed a detailed PK study looking at three different formulations of 1,200mg of oral LA that shows that there are differences in PK parameters of LA made by different manufacturers (unpublished data). This study shows that there remains considerable variability in the PK parameters between subjects (unpublished data).

Thus, the single published clinical study on MS shows that high-dose oral LA is safe, reasonably tolerated, and capable of reducing serum MMP-9 and sICAM-1 levels.17 Whether similar results can be seen in subsequent studies needs to be determined. Based on EAE studies and the preliminary results from this clinical trial, LA appears to have a potential of a useful drug in treating MS.

Conclusion

Based on the EAE work, LA appears to be an effective anti-inflammatory therapeutic agent. A preliminary clinical trial in MS patients demonstrated that high-dose LA administration is safe. Larger phase II/III clinical trials are warranted to assess the clinical efficacy of LA in MS. Further studies to better understand the mechanism of action of LA are under way. The use of oral LA as a potential treatment for MS will be a major breakthrough in MS therapeutics.